BioPharmSignal logoBioPharmSignal

Biotech News

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Technologies, Inc. (OSUR)OraSure Technologies, Inc.FDA / regulatory

Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic

Related news

OSUROraSure Technologies, Inc.2026-06-11 12:00 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OSUROraSure Technologies, Inc.2026-01-05 13:00 EST

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

DGXQuest Diagnostics2026-06-24 12:52 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

INBSIntelligent Bio Solutions2026-01-28 13:30 EST

Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market

INBSIntelligent Bio Solutions2026-06-02 12:30 EST

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

DGXQuest Diagnostics2026-08-24 11:24 EST

Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology

SERASera Prognostics2026-06-30 20:05 EST

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS

BIAFbioAffinity Technologies, Inc.2026-03-10 11:47 EST

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

BIAFbioAffinity Technologies, Inc.2026-03-03 13:30 EST

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

View all latest news

OraSure Technologies, Inc.

Decentralized Diagnostics OraSure Technologies develops point-of-need and at-home diagnostic tests intended to make testing more accessible, private and convenient. Rapid-Test Portfolio The company's products cover infectious diseases and other conditions across consumer, clinical, public-health and community settings. Subsidiaries...

Recent company news

OSUROraSure Technologies, Inc.2026-08-05 20:05 EST

OraSure Announces Second Quarter 2026 Financial Results

OSUROraSure Technologies, Inc.2026-07-22 20:10 EST

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

OSUROraSure Technologies, Inc.2026-07-21 20:30 EST

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

OSUROraSure Technologies, Inc.2026-06-11 12:00 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OSUROraSure Technologies, Inc.2026-05-06 20:05 EST

OraSure Announces First Quarter 2026 Financial Results

Stock data

Close
3.49 USD
Market cap
275.39M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States